Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Will Get Humira Royalty Revenue Through CAT Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca's acquisition of Cambridge Antibody Technology will give the firm royalty revenues from human monoclonal antibody technologies already licensed out by CAT, including Abbott's rheumatoid arthritis therapy Humira (adalimumab)

You may also be interested in...



AstraZeneca Shifts Abandoned GI Developmental Compounds To New Affiliate

New company Albireo will be financed initially with $27 million from three growth capital firms.

AstraZeneca Shifts Abandoned GI Developmental Compounds To New Affiliate

New company Albireo will be financed initially with $27 million from three growth capital firms.

HGS/GSK On Track To Initiate Lymphostat-B Phase III Study In 2006

Full Phase II study results show promise in treatment of lupus even though Lymphostat-B did not meet primary endpoints, the firm says.

Related Content

Topics

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel